CMPF

CMPF (CAS No.: 86879-39-2) is an endogenous metabolite derived from furan fatty acids that is detectable as a trace constituent in human blood and urine and is recognized as a clinically relevant biomarker associated with metabolic disorders, including type 2 diabetes. This compound exhibits strong binding affinity to serum albumin and plays a significant role in modulating thyroid hormone homeostasis by inhibiting the cellular transport and subsequent deiodination of thyroxine (T4), primarily through indirect mechanisms involving displacement of competing ligands such as free fatty acids and acidic drugs from albumin binding sites. In pathological conditions such as uremia, CMPF can accumulate to relatively high circulating levels, thereby amplifying its effects on hormone distribution and transport. Beyond its endocrine-related activity, CMPF has been shown to directly affect pancreatic β-cell function by impairing mitochondrial activity, reducing glucose-stimulated ATP production, and promoting oxidative stress, which collectively contribute to dysregulated insulin secretion. Conversely, in metabolic disease models, CMPF has demonstrated the capacity to ameliorate hepatic lipid accumulation and improve systemic insulin sensitivity, highlighting a complex and context-dependent biological profile. Although precise potency metrics are not consistently defined, its biological effects are typically observed in low micromolar to submillimolar concentration ranges in vitro. CMPF is widely utilized in studies investigating metabolic dysfunction, mitochondrial biology, thyroid hormone transport, and protein-ligand interactions, with experimental concentrations tailored to specific cellular or in vivo model systems to elucidate its multifaceted roles in disease-related pathways.